craft-sa-dev Home  

PMC:1283364 / 2985-3677 JSONTXT 5 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T846 0-5 JJ denotes Early
T847 6-14 NN denotes evidence
T849 15-19 IN denotes from
T850 20-28 JJ denotes clinical
T851 29-35 NNS denotes trials
T852 36-38 IN denotes of
T853 39-47 NN denotes antibody
T855 47-48 HYPH denotes -
T854 48-56 VBN denotes mediated
T856 57-66 NN denotes clearance
T857 66-68 , denotes ,
T858 68-71 CD denotes one
T859 72-74 IN denotes of
T860 75-78 DT denotes the
T862 79-84 JJ denotes first
T863 85-87 NN denotes Aβ
T865 87-88 HYPH denotes -
T864 88-96 VBG denotes lowering
T861 97-107 NNS denotes approaches
T866 108-114 VBN denotes tested
T867 115-117 IN denotes in
T868 118-124 NNS denotes humans
T869 124-126 , denotes ,
T848 126-135 VBD denotes suggested
T870 136-140 IN denotes that
T872 141-151 NNS denotes treatments
T873 152-160 VBN denotes designed
T874 161-163 TO denotes to
T875 164-170 VB denotes reduce
T876 171-178 NN denotes amyloid
T877 179-185 NN denotes burden
T878 186-189 MD denotes may
T879 190-196 RB denotes indeed
T871 197-199 VB denotes be
T880 200-210 JJ denotes beneficial
T881 210-211 . denotes .
T882 211-503 sentence denotes Although the trials were halted because of adverse effects in a subset of volunteers [4,5], further analysis of several patients found evidence that amyloid pathology, and to a lesser degree cognitive function, was improved in proportion to the patient's titer of Aβ-specific antibody [6,7].
T883 212-220 IN denotes Although
T885 221-224 DT denotes the
T886 225-231 NNS denotes trials
T887 232-236 VBD denotes were
T884 237-243 VBN denotes halted
T889 244-251 IN denotes because
T890 252-254 IN denotes of
T891 255-262 JJ denotes adverse
T892 263-270 NNS denotes effects
T893 271-273 IN denotes in
T894 274-275 DT denotes a
T895 276-282 NN denotes subset
T896 283-285 IN denotes of
T897 286-296 NNS denotes volunteers
T898 297-298 -LRB- denotes [
T900 298-299 CD denotes 4
T901 299-300 , denotes ,
T899 300-301 CD denotes 5
T902 301-302 -RRB- denotes ]
T903 302-304 , denotes ,
T904 304-311 JJ denotes further
T905 312-320 NN denotes analysis
T906 321-323 IN denotes of
T907 324-331 JJ denotes several
T908 332-340 NNS denotes patients
T888 341-346 VBD denotes found
T909 347-355 NN denotes evidence
T910 356-360 IN denotes that
T912 361-368 NN denotes amyloid
T913 369-378 NN denotes pathology
T914 378-380 , denotes ,
T915 380-383 CC denotes and
T916 384-386 IN denotes to
T918 387-388 DT denotes a
T920 389-395 JJR denotes lesser
T919 396-402 NN denotes degree
T921 403-412 JJ denotes cognitive
T917 413-421 NN denotes function
T922 421-423 , denotes ,
T923 423-426 VBD denotes was
T911 427-435 VBN denotes improved
T924 436-438 IN denotes in
T925 439-449 NN denotes proportion
T926 450-452 IN denotes to
T927 453-456 DT denotes the
T928 457-464 NN denotes patient
T930 464-466 POS denotes 's
T929 467-472 NN denotes titer
T931 473-475 IN denotes of
T932 476-478 NN denotes Aβ
T934 478-479 HYPH denotes -
T933 479-487 JJ denotes specific
T935 488-496 NN denotes antibody
T936 497-498 -LRB- denotes [
T938 498-499 CD denotes 6
T939 499-500 , denotes ,
T937 500-501 CD denotes 7
T940 501-502 -RRB- denotes ]
T941 502-503 . denotes .
T942 503-692 sentence denotes While this approach is promising, constant exposure to antibodies that recognize an epitope highly enriched in the brain may have unexpected side effects that will limit its long-term use.
T943 504-509 IN denotes While
T945 510-514 DT denotes this
T946 515-523 NN denotes approach
T944 524-526 VBZ denotes is
T948 527-536 JJ denotes promising
T949 536-538 , denotes ,
T950 538-546 JJ denotes constant
T951 547-555 NN denotes exposure
T952 556-558 IN denotes to
T953 559-569 NNS denotes antibodies
T954 570-574 WDT denotes that
T955 575-584 VBP denotes recognize
T956 585-587 DT denotes an
T957 588-595 NN denotes epitope
T958 596-602 RB denotes highly
T959 603-611 VBN denotes enriched
T960 612-614 IN denotes in
T961 615-618 DT denotes the
T962 619-624 NN denotes brain
T963 625-628 MD denotes may
T947 629-633 VB denotes have
T964 634-644 JJ denotes unexpected
T966 645-649 NN denotes side
T965 650-657 NNS denotes effects
T967 658-662 WDT denotes that
T969 663-667 MD denotes will
T968 668-673 VB denotes limit
T970 674-677 PRP$ denotes its
T972 678-682 JJ denotes long
T974 682-683 HYPH denotes -
T973 683-687 NN denotes term
T971 688-691 NN denotes use
T975 691-692 . denotes .
R457 T846 T847 amod Early,evidence
R458 T847 T848 nsubj evidence,suggested
R459 T849 T847 prep from,evidence
R460 T850 T851 amod clinical,trials
R461 T851 T849 pobj trials,from
R462 T852 T851 prep of,trials
R463 T853 T854 npadvmod antibody,mediated
R464 T854 T856 amod mediated,clearance
R465 T855 T854 punct -,mediated
R466 T856 T852 pobj clearance,of
R467 T857 T856 punct ", ",clearance
R468 T858 T856 appos one,clearance
R469 T859 T858 prep of,one
R470 T860 T861 det the,approaches
R471 T861 T859 pobj approaches,of
R472 T862 T861 amod first,approaches
R473 T863 T864 npadvmod Aβ,lowering
R474 T864 T861 amod lowering,approaches
R475 T865 T864 punct -,lowering
R476 T866 T861 acl tested,approaches
R477 T867 T866 prep in,tested
R478 T868 T867 pobj humans,in
R479 T869 T848 punct ", ",suggested
R480 T870 T871 mark that,be
R481 T871 T848 ccomp be,suggested
R482 T872 T871 nsubj treatments,be
R483 T873 T872 acl designed,treatments
R484 T874 T875 aux to,reduce
R485 T875 T873 advcl reduce,designed
R486 T876 T877 compound amyloid,burden
R487 T877 T875 dobj burden,reduce
R488 T878 T871 aux may,be
R489 T879 T871 advmod indeed,be
R490 T880 T871 acomp beneficial,be
R491 T881 T848 punct .,suggested
R492 T883 T884 mark Although,halted
R493 T884 T888 advcl halted,found
R494 T885 T886 det the,trials
R495 T886 T884 nsubjpass trials,halted
R496 T887 T884 auxpass were,halted
R497 T889 T884 prep because,halted
R498 T890 T889 pcomp of,because
R499 T891 T892 amod adverse,effects
R500 T892 T889 pobj effects,because
R501 T893 T892 prep in,effects
R502 T894 T895 det a,subset
R503 T895 T893 pobj subset,in
R504 T896 T895 prep of,subset
R505 T897 T896 pobj volunteers,of
R506 T898 T899 punct [,5
R507 T899 T884 parataxis 5,halted
R508 T900 T899 nummod 4,5
R509 T901 T899 punct ",",5
R510 T902 T899 punct ],5
R511 T903 T888 punct ", ",found
R512 T904 T905 amod further,analysis
R513 T905 T888 nsubj analysis,found
R514 T906 T905 prep of,analysis
R515 T907 T908 amod several,patients
R516 T908 T906 pobj patients,of
R517 T909 T888 dobj evidence,found
R518 T910 T911 mark that,improved
R519 T911 T909 acl improved,evidence
R520 T912 T913 compound amyloid,pathology
R521 T913 T911 nsubjpass pathology,improved
R522 T914 T913 punct ", ",pathology
R523 T915 T913 cc and,pathology
R524 T916 T917 prep to,function
R525 T917 T913 conj function,pathology
R526 T918 T919 det a,degree
R527 T919 T916 pobj degree,to
R528 T920 T919 amod lesser,degree
R529 T921 T917 amod cognitive,function
R530 T922 T911 punct ", ",improved
R531 T923 T911 auxpass was,improved
R532 T924 T911 prep in,improved
R533 T925 T924 pobj proportion,in
R534 T926 T925 prep to,proportion
R535 T927 T928 det the,patient
R536 T928 T929 poss patient,titer
R537 T929 T926 pobj titer,to
R538 T930 T928 case 's,patient
R539 T931 T929 prep of,titer
R540 T932 T933 npadvmod Aβ,specific
R541 T933 T935 amod specific,antibody
R542 T934 T933 punct -,specific
R543 T935 T931 pobj antibody,of
R544 T936 T937 punct [,7
R545 T937 T911 parataxis 7,improved
R546 T938 T937 nummod 6,7
R547 T939 T937 punct ",",7
R548 T940 T937 punct ],7
R549 T941 T888 punct .,found
R550 T943 T944 mark While,is
R551 T944 T947 advcl is,have
R552 T945 T946 det this,approach
R553 T946 T944 nsubj approach,is
R554 T948 T944 acomp promising,is
R555 T949 T947 punct ", ",have
R556 T950 T951 amod constant,exposure
R557 T951 T947 nsubj exposure,have
R558 T952 T951 prep to,exposure
R559 T953 T952 pobj antibodies,to
R560 T954 T955 dep that,recognize
R561 T955 T953 relcl recognize,antibodies
R562 T956 T957 det an,epitope
R563 T957 T955 dobj epitope,recognize
R564 T958 T959 advmod highly,enriched
R565 T959 T957 amod enriched,epitope
R566 T960 T959 prep in,enriched
R567 T961 T962 det the,brain
R568 T962 T960 pobj brain,in
R569 T963 T947 aux may,have
R570 T964 T965 amod unexpected,effects
R571 T965 T947 dobj effects,have
R572 T966 T965 compound side,effects
R573 T967 T968 dep that,limit
R574 T968 T965 relcl limit,effects
R575 T969 T968 aux will,limit
R576 T970 T971 poss its,use
R577 T971 T968 dobj use,limit
R578 T972 T973 amod long,term
R579 T973 T971 compound term,use
R580 T974 T973 punct -,term
R581 T975 T947 punct .,have